Elizabeth H.Z. Thompson

Dr. Elizabeth H.Z. Thompson joined Horizon in June 2018 as an accomplished drug development professional with two decades of experience and roles in the development of multiple marketed medications. In her time at Horizon, she has been responsible for the guidance of clinical development activities across the portfolio, including the expedited filing and approval of TEPEZZA and its successful FDA Advisory Committee meeting.

Before joining Horizon, Dr. Thompson was a group scientific director in pharmaceutical development at AbbVie, where she was the clinical lead for risankizumab (SKYRIZI), supporting global submissions and approvals. Before AbbVie, Dr. Thompson has had a career spanning clinical development, business development and medical communications, and has also worked at Raptor, InterMune and Amgen.

Dr. Thompson holds a bachelor’s degree in chemistry from Harvey Mudd College and a doctorate in macromolecular and cellular structure and chemistry from the Scripps Research Institute. She is a member of the Americares Bay Area Committee Leadership Council.